Phage II Trial of Stathmin as Predictive Biomarker for TPF Induction Chemotherapy in OSCC

Recruiting now · Phase 2

Conditions studied: Neoplasm Neck

In brief

To investigate the predictive value of stathmin expression as a predictive biomarker in OSCC patients, who treated with TPF (docetaxel, cisplatin and 5-fluorouracil ) induction chemotherapy followed by radical surgery and radiotherapy/chemoradiotherapy.

Key facts

Study ID
NCT03326947
Run by
Shanghai Jiao Tong University School of Medicine
People needed
60
Starts
2018-01-01
Expected to finish
2027-01-01
Last updated by the study team
2024-02-20

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.